US Edition
News from redaccionmedica.com
We’ve assigned a media bias rating of unknown to redaccionmedica.com. You can read more about our methodology here.
Information about redaccionmedica.com
Where is redaccionmedica.com located?redaccionmedica.com's WebsiteMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top redaccionmedica.com News
Pedro Sánchez · SpainSpain’s Prime Minister Pedro Sánchez has announced the creation of a sovereign wealth fund, España Crece, designed to mobilise up to €120 billion in investment across strategic sectors of the Spanish economy. The fund was unveiled during the closing session of the Spain Investors Day forum, where Sánchez outlined its objectives, structure and priorities. The initiative is part of a broader… SourceSee the Story
Spain to Launch Sovereign Wealth Fund to Extend Stimulus ...
37% Center coverage: 11 sources
Pedro Sánchez · BadajozThe socialist Miguel Ángel Gallardo, who resigned on 22 December as secretary general of the PSOE of Extremadura after the bad results achieved in the regional elections, has now, by surprise, resigned to collect his act of deputy in the Assembly of Extremadura, as he himself announced in his account of X. "It has been an honor to serve and share so many years of commitment, effort and learning with so many wonderful people. But today I take a s…See the Story
Gallardo Resigns His Act of Deputy in the Assembly of Extremadura and Ceases to Be Held in the Case of Sánchez's Brother
63% Right coverage: 8 sources
Spain · SpainLynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancersNOUS-209 is an off-the-shelf cancer immunotherapy designed to induce T cells against neoantigens present in tumors and precancer lesions in LS carriersPublication in Nature Medicine underscores significance of NOUS-209 clinical data and its innovative approach to intercept cancer before it developsData support advanci…See the Story
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
50% Center coverage: 4 sources
